Zevra Therapeutics, Inc. (ZVRA) Stock Analysis & Investment Frameworks
Zevra Therapeutics, Inc. (ZVRA) stock analysis on Invetso. Review Zevra Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Zevra Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Zevra Therapeutics, Inc. Key Financial Metrics
- Market Cap: $619.97M
- Revenue: $106.47M
- P/E Ratio: 7.46
- ROE: 32.77%
- ROIC: 12.90%
- Dividend Yield: N/A
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Zevra Therapeutics, Inc. Investment Frameworks
Invetso analyzes Zevra Therapeutics, Inc. (ZVRA) across the following frameworks:
- Zevra Therapeutics, Inc. 10Y Growth Potential
- Zevra Therapeutics, Inc. Scenario Analysis
- Zevra Therapeutics, Inc. Risks & Opportunities
- Zevra Therapeutics, Inc. Economic Moat
- Zevra Therapeutics, Inc. Business Model
- Zevra Therapeutics, Inc. Management
- Zevra Therapeutics, Inc. SWOT Analysis
- Zevra Therapeutics, Inc. Porter's 5 Forces
- Zevra Therapeutics, Inc. PESTLE Analysis
- Zevra Therapeutics, Inc. ESG Analysis